Substituted 7-methyl quinoline derivatives for drug-resistant tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antitubercular drugs face challenges due to the emergence of drug-resistant tuberculosis strains, limited new drug approvals, and significant side effects, necessitating the development of novel compounds with new molecular mechanisms of action.
Innovation Solution
A series of substituted 7-methyl quinoline derivatives have been synthesized and purified, exhibiting anti-tubercular activity against Mycobacterium tuberculosis, including multi-drug resistance strains, through a synthetic chemical method and column chromatographic purification, with specific compounds showing promise at millimolar to micromolar concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-TB drugs are used, then tuberculosis treatment is achieved, but drug resistance develops and side effects occur
Solution Approach 1:
The invention segments the treatment approach by introducing a novel chemical structure class (7-methyl-1H-indole-2-carboxamide derivatives) with distinct molecular scaffolds from conventional drugs. This structural segmentation enables new mechanisms of action that bypass existing resistance pathways while maintaining therapeutic effectiveness against MDR-TB strains.
Solution Approach 2:
The invention applies parameter changes by systematically varying molecular parameters including substituents at positions R1-R6, R8-R12, and core structure modifications. These parameter changes generate a library of derivatives with optimized pharmacological properties, achieving both effectiveness against resistant strains and reduced toxicity profiles compared to conventional drugs.
2Object-affected harmful factors
If new antitubercular drugs are developed, then resistance issues are reduced, but the number of approved drugs remains limited
Solution Approach 1:
The invention performs preliminary action by conducting extensive in silico molecular docking studies and in vitro biological evaluations before clinical development. The compounds have been pre-screened for activity against MDR-TB strains and shown to inhibit mycobacterial targets, accelerating the development pipeline and increasing the likelihood of successful approval while addressing resistance issues.
3Reliability
If substituted 7-methyl quinoline derivatives are synthesized, then anti-TB activity against MDR strains is achieved, but synthesis and purification complexity increases
Solution Approach 1:
The invention applies local quality by introducing specific functional groups at defined positions (R1-R6, R8-R12) on the quinoline core structure. Each substituent placement is optimized to enhance anti-TB activity against MDR strains while maintaining reasonable synthetic accessibility. The modular substitution pattern allows systematic optimization of local molecular properties to achieve desired biological effects.
Data Source
AI summary
Compounds for treating tuberculosis and, particularly, antitubercular compounds that are substituted 7-methyl quinoline derivatives and their use as antitubercular agents are provided.